Pharmacologic Treatment of Perinatal Depression

Obstetrics and Gynecology Clinics of North America

Volumn 45, Issue 3, 2018, Pages 419-440

  Kimmel, Mary C ^a   Cox, Elizabeth ^a   Schiller, Crystal ^a   Gettes, Edith ^a   Meltzer Brody, Samantha ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Medication; Mental health; Peripartum; Treatment considerations

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; IRENKA; ISOCARBOXAZID; LAMOTRIGINE; LITHIUM; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; QUETIAPINE; SELEGILINE; SERAFEM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

ADAPTATION SYNDROME; AUTISM; DRUG DOSE INCREASE; DRUG LABELING; DRUG MONITORING; DRUG SAFETY; HUMAN; PERINATAL DEPRESSION; PERSISTENT PULMONARY HYPERTENSION; POSTNATAL DEPRESSION; PREECLAMPSIA; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SMALL FOR DATE INFANT; SPONTANEOUS ABORTION; TERATOGENICITY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTRAINDICATION; DEPRESSION; FEMALE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PRENATAL EXPOSURE; PREVENTION AND CONTROL; PSYCHOLOGY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL DECISION-MAKING; CONTRAINDICATIONS; DEPRESSION; FEMALE; HUMANS; PRACTICE PATTERNS, PHYSICIANS'; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANT WOMEN; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTHERAPY; RISK ASSESSMENT;

EID: 85051024940     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2018.04.007     Document Type: Review

References (165)

1. World Health Organisation. ICD-10 classifications of mental and behavioural disorder: clinical descriptions and diagnostic guidelines. 1992.
2. American Psychiatric Association, Diagnostic and statistical manual of mental disorders. 5th edition, 2013, American Psychiatric Publishing, Arlington (VA).
3. Gaynes, B., Gavin, N., Meltzer-Brody, S., Perinatal depression: prevalence, screening accuracy and screening outcomes. Evid Rep Technol Assess 119 (2005), 1–8.
4. Elisei, S., Lucarini, E., Murgia, N., et al. Perinatal depression: a study of prevalence and of risk and protective factors. Psychiatr Danub 25 (2013), S258–S262.
5. Cox, E.Q., Sowa, N.A., Meltzer-Brody, S.E., et al. The perinatal depression treatment cascade: baby steps toward improving outcomes. J Clin Psychiatry 77:9 (2016), 1189–1200.
6. Grigoriadis, S., VonderPorten, E.H., Mamisashvili, L., et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 74:4 (2013), 321–341.
7. Herring, S.J., Rich-Edwards, J.W., Oken, E., et al. Association of postpartum depression with weight retention 1 year after childbirth. Obesity 16 (2008), 1296–1301.
8. Qiu, C., Williams, M.A., Calderon-Margalit, R., et al. Preeclampsia risk in relation to maternal mood and anxiety disorders diagnosed before or during early pregnancy. Am J Hypertens 22 (2009), 397–402.
9. Meltzer-Brody, S., Bledsoe-Mansori, S.E., Johnson, N., et al. A prospective study of perinatal depression and trauma history in pregnant minority adolescents. Am J Obstet Gynecol 208:211 (2013), e1–e7.
10. Milgrom, J., Gemmill, A.W., Bilszta, J.L., et al. Antenatal risk factors for postnatal depression: a large prospective study. J Affect Disord 108 (2008), 147–157.
11. Garner, A.S., Shonkoff, J.P. Committee on Psychosocial Aspects of Child and Family Health Committee on Early Childhood, Adoption, and Dependent Care, Section on Developmental and Behavioral Pediatrics. Early childhood adversity, toxic stress, and the role of the pediatrician: translating developmental science into lifelong health. Pediatrics 129:1 (2012), e224–e231.
12. Earls MF, T.C.o.P.A.o.C.a.F. Health. Clinical report – Incorporating recognition and management of perinatal and postpartum depression into pediatric practice American Academy of Pediatrics, 2010.
13. Shonkoff, J.P., Garner, A.S. Committee on Psychosocial Aspects of Child and Family Health Committee on Early Childhood, Adoption, and Dependent Care, Section on Developmental and Behavioral Pediatrics. The lifelong effects of early childhood adversity and toxic stress. Pediatrics 129:1 (2012), e232–e246.
14. National Scientific Council on the Developing Child, Center on the Developing Child at Harvard University. Excessive stress disrupts the architecture of the developing brain: paper #3. 2005, National Scientific Council on the Developing Child, Center on the Developing Child at Harvard University, Cambridge (MA).
15. National Scientific Council on the Developing Child. Early Experiences Can Alter Gene Expression and Affect Long-Term Development: Working Paper #10. 2010 Available at: http://www.developingchild.net.
16. Dawson, G., Ashman, S., On the origins of a vulnerability to depression: the influence of the early social environment on the development of psychobiological systems related to risk for affective disorder. Nelson, C., (eds.) The effects of adversity on neurobehavioral development: Minnesota symposium on child psychology, 2000, Lawrence Erlbaum & Assoc, Mahwah (NJ), 245–280.
17. Ashman, S., Dawson, G., Panagiotides, H., et al. Stress hormone levels of children of depressed mothers. Dev Psychopathol 14:2 (2002), 333–349.
18. Essex, M.J., Klein, M.H., Cho, E., et al. Maternal stress beginning in infancy may sensitize children to later stress exposure: effects on cortisol and behavior. Biol Psychiatry 52:8 (2002), 776–784.
19. Dennis, C., McQueen, K., The relationship between infant-feeding outcomes and postpartum depression: a qualitative systematic review. Pediatrics 123:4 (2009), 736–751.
20. Woolhouse, H., Gartland, D., Mensah, F., et al. Maternal depression from early pregnancy to 4 years postpartum in a prospective pregnancy cohort study: implications for primary health care. BJOG, 2014, 10.1111/1471-0528.12837.
21. Lindahl, V., Pearson, J., Colpe, L., Prevalence of suicidality during pregnancy and postpartum. Arch Womens Ment Health 8:2 (2005), 77–87.
22. Yonkers, K.A., Wisner, K.L., Stewart, D.E., et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31 (2009), 403–413.
23. Battle, C.L., Salisbury, A.L., Schofield, C.A., et al. Perinatal antidepressant use: understanding women's preferences and concerns. J Psychiatr Pract 19:6 (2013), 443–453.
24. Goodman, J.H., Women's attitudes, preferences, and perceived barriers to treatment for perinatal depression. Birth 36:1 (2009), 60–69.
25. Claridge, A.M., Efficacy of systematically oriented psychotherapies in the treatment of perinatal depression: a meta analysis. Arch Womens Ment Health 17 (2014), 3–15.
26. Grote, N.K., Swartz, H.A., Geibel, S.L., et al. A randomized controlled trial of culturally relevant, brief interpersonal psychotherapy for perinatal depression. Psychiatr Serv 60:3 (2009), 313–321.
27. Spinelli, M.G., Endicott, J., Leon, A.C., et al. A controlled clinical treatment trial of interpersonal psychotherapy for depressed pregnant women at 3 New York City sites. J Clin Psychiatry 74:4 (2013), 393–399.
28. Sockol, L.E., Epperson, C.N., Barber, J.P., A meta-analysis of treatments for perinatal depression. Clin Psychol Rev 31:5 (2011), 839–849.
29. O'Hara, M.W., McCabe, J.E., Postpartum depression: current status and future directions. Annu Rev Clin Psychol 9 (2013), 379–407.
30. Wisner, K.L., Zarin, D.A., Holmboe, E.S., et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 157:12 (2000), 1933–1940.
31. O'Hara, M., Swain, A.W., Rates and risk of postpartum depression-a meta-analysis. Int Rev Psychiatry 8:1 (1996), 37–54.
32. Schiller, C.E., Meltzer-Brody, S., Rubinow, D.R., The role of reproductive hormones in postpartum depression. CNS Spectr 20:1 (2015), 48–59.
33. FDA, Medication Guides, 2017, U.S. Department of Health and Human Services.
34. Weisskopf, E., Fischer, C.J., Bickle Graz, M., et al. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence. Expert Opin Drug Saf 14:3 (2015), 413–427.
35. Mann, J., The medical management of depression. N Engl J Med 353:17 (2005), 1819–1834.
36. Kroenke, K., West, S.L., Swindle, R., Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286 (2001), 2947–2955.
37. Stahl, S., Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48 (2000), 894–901.
38. Huybrechts, K.F., Sanghani, R.S., Avorn, J., et al. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One, 9(3), 2014, e92778.
39. Andersen, J.T., Andersen, N.L., Horwitz, H., et al. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. Obstet Gynecol 124:4 (2014), 655–661.
40. Sujan, A.C., Rickert, M.E., Oberg, A.S., et al. Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA 317:15 (2017), 1553–1562.
41. Liu, X., Agerbo, E., Ingstrup, K.G., et al. Antidepressant use during pregnancy and psychiatric disorders in offspring: Danish nationwide register based cohort study. BMJ, 358, 2017, j3668.
42. Huybrechts, K.F., Palmsten, K., Avorn, J., et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370:25 (2014), 2397–2407.
43. Chambers, C.D., Hernandez-Diaz, S., Van Marter, L.J., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354:6 (2006), 579–587.
44. Wilson, K.L., Zelig, C.M., Harvey, J.P., et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 28:1 (2011), 19–24.
45. US Food and Drug Administration (FDA). FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. 2011. Available at: https://www.fda.gov/Drugs/DrugSafety/ucm283375.htm. Accessed October 20, 2017.
46. Huybrechts, K.F., Bateman, B.T., Palmsten, K., et al. Antidepressant use in late pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313:21 (2015), 2142–2151.
47. Levinson-Castiel, R., Merlob, P., Linder, N., et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160:2 (2006), 173–176.
48. Oberlander, T.F., Misri, S., Fitzgerald, C.E., et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 65:2 (2004), 230–237.
49. Moses-Kolko, E.L., Bogen, D., Perel, J., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:19 (2005), 2372–2383.
50. Forsberg, L., Navér, L., Gustafsson, L.L., et al. Neonatal adaptation in infants prenatally exposed to antidepressants- clinical monitoring using neonatal abstinence score. PLoS One, 9(11), 2014, e111327.
51. Warburton, W., Hertzman, C., Oberlander, T.F., A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 121:6 (2010), 471–479.
52. Kieviet, N., Dolman, K.M., Honig, A., The use of psychotropic medication during pregnancy: how about the newborn?. Neuropsychiatr Dis Treat 9 (2013), 1257–1266.
53. Nulman, I., Koren, G., Rovet, J., et al. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study. J Clin Psychiatry 76:7 (2015), e842–e847.
54. Croen, L.A., Grether, J.K., Yoshida, C.K., et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68:11 (2011), 1104–1112.
55. Rai, D., Lee, B.K., Dalman, C., et al. Parental depression, maternal antidepressant use during pregnancy, and the risk of autism spectrum disorders: population based case-control study. BMJ, 346, 2013, f2059.
56. Boukhris, T., Sheehy, O., Mottron, L., et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 170:2 (2016), 117–124.
57. Andrade, C., Antidepressant exposure during pregnancy and risk of autism in the offspring, 1: meta-review of meta-analyses. J Clin Psychiatry 78:8 (2017), e1047–e1051.
58. Castro, V.M., Kong, S.W., Clements, C.C., et al. Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study. Transl Psychiatry, 6, 2016, e708.
59. Oberlander, T.F., Gingrich, J.A., Ansorge, M.S., Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 86:6 (2009), 672–677.
60. Wisner, K.L., Bogen, D.L., Sit, D., et al. Does fetal exposure to SSRIs or maternal depression impact infant growth?. Am J Psychiatry 170:5 (2013), 485–493.
61. Santucci, A.K., Singer, L.T., Wisniewski, S.R., et al. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes. J Clin Psychiatry 75:10 (2014), 1088–1095.
62. Rush, A., Fava, M., Wisniewski, S.R., et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:1 (2004), 119–142.
63. Gaynes, B.N., Warden, D., Trivedi, M.H., et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60:11 (2009), 1439–1445.
64. Lambert, O., Bourin, M., SNRIs: mechanism of action and clinical features. Expert Rev Neurother 2:6 (2002), 849–858.
65. Laurent, L., Huang, C., Ernest, S.R., et al. In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat. Birth Defects Res A Clin Mol Teratol 106:12 (2016), 1044–1055.
66. Selmer, R., Haglund, B., Furu, K., et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf 25:10 (2016), 1160–1169.
67. Bellantuono, C., Vargas, M., Mandarelli, G., et al. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol 30:3 (2015), 143–151.
68. Einarson, A., Fatoye, B., Sarkar, M., et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 158:10 (2001), 1728–1730.
69. Lassen, D., Ennis, Z.N., Damkier, P., First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol Toxicol 118:1 (2016), 32–36.
70. Einarson, A., Smart, K., Vial, T., et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry, 73(11), 2012, 1471.
71. Berard, A., Sheehy, O., Zhao, J.P., et al. SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn. Br J Clin Pharmacol 83:5 (2017), 1126–1133.
72. Ewing, G., Tatarchuk, Y., Appleby, D., et al. Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome. Clin Pharmacokinet 54:4 (2015), 359–370.
73. Holland, J., Brown, R., Neonatal venlafaxine discontinuation syndrome: a mini-review. Eur J Paediatr Neurol 21:2 (2017), 264–268.
74. National Institutes of Health. TOXNET Toxicology Data Network. Available at: https://toxnet.nlm.nih.gov. Accessed October 20, 2017.
75. Kumari, A., Singh, M., Trigunayat, A., et al. Prenatal desvenlafaxine induced behavioral alterations in Swiss albino mice. Ann Neurosci 21:1 (2014), 19–21.
76. Anthenelli, R.M., Benowitz, N.L., West, R., et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387:10037 (2016), 2507–2520.
77. Hughes, J.R., Stead, L.F., Hartmann-Boyce, J., et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev(1), 2014 CD000031.
78. Baraona, L.K., Lovelace, D., Daniels, J.L., et al. Tobacco harms, nicotine pharmacology, and pharmacologic tobacco cessation interventions for women. J Midwifery Womens Health 62:3 (2017), 253–269.
79. Anttila, S.A., Leinonen, E.V., A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7:3 (2001), 249–264.
80. Watanabe, N., Omori, I.M., Nakagawa, A., et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev(12), 2011 CD006528.
81. Cole, J.A., Modell, J.G., Haight, B.R., et al. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16:5 (2007), 474–484.
82. Thyagarajan, V., Robin Clifford, C., Wurst, K.E., et al. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. Pharmacoepidemiol Drug Saf 21:11 (2012), 1240–1242.
83. Alwan, S., Reefhuis, J., Botto, L.D., et al. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol, 203(1), 2010, 52.e1-6.
84. Louik, C., Kerr, S., Mitchell, A.A., First-trimester exposure to bupropion and risk of cardiac malformations. Pharmacoepidemiol Drug Saf 23:10 (2014), 1066–1075.
85. Fokina, V.M., West, H., Oncken, C., et al. Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid. Am J Obstet Gynecol, 215(4), 2016, 497.e1-7.
86. Smit, M., Dolman, K.M., Honig, A., Mirtazapine in pregnancy and lactation - A systematic review. Eur Neuropsychopharmacol 26:1 (2016), 126–135.
87. Burkey, B.W., Holmes, A.P., Evaluating medication use in pregnancy and lactation: what every pharmacist should know. J Pediatr Pharmacol Ther 18:3 (2013), 247–258.
88. Lopez-Munoz, F., Alamo, C., Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:14 (2009), 1563–1586.
89. Carvalho, A.F., Sharma, M.S., Brunoni, A.R., et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 85:5 (2016), 270–288.
90. Gracious, B.L., Wisner, K.L., Phenelzine use throughout pregnancy and the puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 6:3 (1997), 124–128.
91. ACOG Committee on Practice Bulletins–Obstetrics, ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111:4 (2008), 1001–1020.
92. Ramos, E., St-André, M., Rey, E., et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 192:5 (2008), 344–350.
93. Einarson, A., Bonari, L., Voyer-Lavigne, S., et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry 48:2 (2003), 106–110.
94. Ram, D., Gandotra, S., Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation. Indian J Psychiatry 57:Suppl 2 (2015), S354–S371.
95. Berard, A., Zhao, J.P., Sheehy, O., Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open, 7(1), 2017, e013372.
96. Nulman, I., Rovet, J., Stewart, D.E., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:4 (1997), 258–262.
97. Nulman, I., Rovet, J., Stewart, D.E., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 159:11 (2002), 1889–1895.
98. Simon, G.E., Cunningham, M.L., Davis, R.L., Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159:12 (2002), 2055–2061.
99. Patorno, E., Huybrechts, K.F., Bateman, B.T., et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 376:23 (2017), 2245–2254.
100. Haskey, C., Galbally, M., Mood stabilizers in pregnancy and child developmental outcomes: a systematic review. Aust N Z J Psychiatry 51:11 (2017), 1087–1097.
101. Bromley, R.L., Weston, J., Marson, A.G., Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 318:17 (2017), 1700–1701.
102. Ornoy, A., Weinstein-Fudim, L., Ergaz, Z., Antidepressants, antipsychotics, and mood stabilizers in pregnancy: what do we know and how should we treat pregnant women with depression. Birth Defects Res 109:12 (2017), 933–956.
103. Ramoz, L.L., Patel-Shori, N.M., Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy 34:4 (2014), 389–395.
104. Dinatale, M., Sahin, L., Johnson, T., et al. Medication use during pregnancy and lactation: introducing the pregnancy and lactation labeling rule. Pediatr Allergy Immunol Pulmonol 30:2 (2017), 132–134.
105. Whyte, J., FDA implements new labeling for medications used during pregnancy and lactation. Am Fam Physician 94:1 (2016), 12–15.
106. O'Hara, M.W., Schlechte, J.A., Lewis, D.A., et al. Controlled prospective study of postpartum mood disorders: psychological, environmental, and hormonal variables. J Abnorm Psychol 100:1 (1991), 63–73.
107. Bloch, M., Schmidt, P.J., Danaceau, M., et al. Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157:6 (2000), 924–930.
108. Sichel, D.A., Cohen, L.S., Robertson, L.M., et al. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 38:12 (1995), 814–818.
109. Gregoire, A.J., Kumar, R., Everitt, B., et al. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 347:9006 (1996), 930–933.
110. Ahokas, A., Kaukoranta, J., Wahlbeck, K., et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. J Clin Psychiatry 62:5 (2001), 332–336.
111. Wisner, K.L., Sit, D.K., Moses-Kolko, E.L., et al. Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial. J Clin Psychopharmacol 35:4 (2015), 389–395.
112. Lawrie, T.A., Hofmeyr, G.J., De Jager, M., et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br J Obstet Gynaecol 105:10 (1998), 1082–1090.
113. Dichtel, L.E., Lawson, E.A., Schorr, M., et al. Neuroactive steroids and affective symptoms in women across the weight spectrum. Neuropsychopharmacology 43:6 (2018), 1436–1444.
114. Cohen, L.S., Altshuler, L.L., Harlow, B.L., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:5 (2006), 499–508.
115. Section on Breastfeeding, Breastfeeding and the use of human milk. Pediatrics 129:3 (2012), e827–e841.
116. Pinheiro, E., Bogen, D.L., Hoxha, D., et al. Sertraline and breastfeeding: review and meta-analysis. Arch Womens Ment Health 18:2 (2015), 139–146.
117. Mojtabai, R., Nonremission and time to remission among remitters in major depressive disorder: revisiting STAR*D. Depress Anxiety 34:12 (2017), 1123–1133.
118. First, M.B., Spitzer, R.L., Gibbon, M., et al. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCID-I/NP). 2002, N.Y.S.P.I. Biometrics Research, New York.
119. Patel, R., Reiss, P., Shetty, H., et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ, 5(12), 2015, e008341.
120. Azorin, J.M., Angst, J., Gamma, A., et al. Identifying features of bipolarity in patients with first-episode postpartum depression: findings from the international BRIDGE study. J Affect Disord 136:3 (2012), 710–715.
121. Mandelli, L., Souery, D., Bartova, L., et al. Bipolar II disorder as a risk factor for postpartum depression. J Affect Disord 204 (2016), 54–58.
122. Altemus, M., Neeb, C.C., Davis, A., et al. Phenotypic differences between pregnancy-onset and postpartum-onset major depressive disorder. J Clin Psychiatry 73:12 (2012), e1485–e1491.
123. Dean, C., Kendell, R.E., The symptomatology of puerperal illnesses. Br J Psychiatry 139 (1981), 128–133.
124. Epperson, C.N., Gueorguieva, R., Czarkowski, K.A., et al. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology (Berl) 186:3 (2006), 425–433.
125. Paul, S.M., Purdy, R.H., Neuroactive steroids. FASEB J 6:6 (1992), 2311–2322.
126. Majewska, M.D., Harrison, N.L., Schwartz, R.D., et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232:4753 (1986), 1004–1007.
127. Deligiannidis, K.M., Kroll-Desrosiers, A.R., Mo, S., et al. Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinology 70 (2016), 98–107.
128. Nappi, R.E., Petraglia, F., Luisi, S., et al. Serum allopregnanolone in women with postpartum “blues”. Obstet Gynecol 97:1 (2001), 77–80.
129. Luisi, S., Petraglia, F., Benedetto, C., et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 85:7 (2000), 2429–2433.
130. Maguire, J., Mody, I., GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron 59:2 (2008), 207–213.
131. Kanes, S.J., Colquhoun, H., Doherty, J., et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol, 32(2), 2017, e2576 1–6.
132. Kanes, S., Colquhoun, H., Gunduz-Bruce, H., et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390:10093 (2017), 480–489.
133. Sage therapeutics announces brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression. 2017. Available at: http://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-brexanolone-achieves-primary. Accessed October 20, 2017.
134. Barthow, C., Wickens, K., Stanley, T., et al. The Probiotics in Pregnancy Study (PiP Study): rationale and design of a double-blind randomised controlled trial to improve maternal health during pregnancy and prevent infant eczema and allergy. BMC Pregnancy Childbirth, 16(1), 2016, 133.
135. Slykerman, R.F., Hood, F., Wickens, K., et al. Effect of lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebo-controlled trial. EBioMedicine 24 (2017), 159–165.
136. O'Mahony, S.M., Clarke, G., Borre, Y.E., et al. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res 277 (2015), 32–48.
137. Gimenez-Bastida, J.A., Martinez Carreras, L., Moya-Pérez, A., et al. Pharmacological efficacy/toxicity of drugs: a comprehensive update about the dynamic interplay of microbes. J Pharm Sci 107:3 (2018), 778–784.
138. Fonseca, A., Gorayeb, R., Canavarro, M.C., Womens help-seeking behaviours for depressive symptoms during the perinatal period: socio-demographic and clinical correlates and perceived barriers to seeking professional help. Midwifery 31:12 (2015), 1177–1185.
139. Bayrampour, H., McNeil, D.A., Benzies, K., et al. A qualitative inquiry on pregnant women's preferences for mental health screening. BMC Pregnancy Childbirth, 17(1), 2017, 339.
140. Cox, E.Q., Raines, C., Kimmel, M., et al. Comprehensive integrated care model to improve maternal mental health. J Obstet Gynecol Neonatal Nurs 46:6 (2017), 923–930.
141. GlaxoSmithKline, New safety information regarding paroxetine: findings suggest increased risk over other antidepressants, of congenital malformations, following first trimester exposure to paroxetine. 2005, GlaxoSmithKline, Mississauga (Canada).
142. Laughren, T., Approval package for: application number NDA 20-031/S052. 2006, FDA.
143. Rowbotham, M.C., Goli, V., Kunz, N.R., et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110 (2004), 697–706.
144. Nanovskaya, T.N., Oncken, C., Fokina, V.M., et al. Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. Am J Obstet Gynecol 216:4 (2017), 420.e1–420.e9.
145. Berard, A., Zhao, J.P., O Sheehy, Success of smoking cessation interventions during pregnancy. Am J Obstet Gynecol, 215(5), 2016, 611.e1-8.
146. Abramowitz, A., Miller, E.S., Wisner, K.L., Treatment options for hyperemesis gravidarum. Arch Womens Ment Health 20:3 (2017), 363–372.
147. Omay, O., Einarson, A., Is mirtazapine an effective treatment for nausea and vomiting of pregnancy? A case series. J Clin Psychopharmacol 37:2 (2017), 260–261.
148. Khazaie, H., Ghadami, M.R., Knight, D.C., et al. Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. Psychiatry Res 210:3 (2013), 901–905.
149. Wichman, C.L., Stern, T.A., Diagnosing and treating depression during pregnancy. Prim Care Companion CNS Disord 17:2 (2015), 1–11.
150. Nonacs, R., Cohen, L.S., Assessment and treatment of depression during pregnancy: an update. Psychiatr Clin North Am 26:3 (2003), 547–562.
151. Rihmer, Z., Gonda, X., Rihmer, A., et al. Antidepressant-resistant depression and the bipolar spectrum – diagnostic and therapeutic considerations. Psychiatr Hung 31:2 (2016), 157–168 [in Hungarian].
152. Barbee, J.G., Thompson, T.R., Jamhour, N.J., et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 72:10 (2011), 1405–1412.
153. Bruno, A., Micò, U., Pandolfo, G., et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26:11 (2012), 1456–1462.
154. Khalkhali, M., Aram, S., Zarrabi, H., et al. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry 11:2 (2016), 104–114.
155. O'Hara, M.W., Wisner, K.L., Perinatal mental illness: definition, description and aetiology. Best Pract Res Clin Obstet Gynaecol 28:1 (2014), 3–12.
156. Naguy, A., Al-Enezi, N., Lamotrigine uses in psychiatric practice-beyond bipolar prophylaxis a hope or hype?. Am J Ther, 2017 [Epub ahead of print].
157. Mohamed, S., Johnson, G.R., Chen, P., et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 318:2 (2017), 132–145.
158. Sharma, V., Smith, A., Mazmanian, D., Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord 8:4 (2006), 400–404.
159. Baastrup, P.C., Schou, M., Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16:2 (1967), 162–172.
160. Rush, A.J., Trivedi, M.H., Wisniewski, S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:11 (2006), 1905–1917.
161. Bergink, V., Burgerhout, K.M., Koorengevel, K.M., et al. Treatment of psychosis and mania in the postpartum period. Am J Psychiatry 172:2 (2015), 115–123.
162. Bergink, V., Bouvy, P.F., Vervoort, J.S., et al. Prevention of postpartum psychosis and mania in women at high risk. Am J Psychiatry 169:6 (2012), 609–615.
163. Austin, M.P., Puerperal affective psychosis: is there a case for lithium prophylaxis?. Br J Psychiatry 161 (1992), 692–694.
164. Cohen, L.S., Sichel, D.A., Robertson, L.M., et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 152:11 (1995), 1641–1645.
165. Wisner, K.L., Hanusa, B.H., Peindl, K.S., et al. Prevention of postpartum episodes in women with bipolar disorder. Biol Psychiatry 56:8 (2004), 592–596.